Literature DB >> 33704702

Model Systems for the Study of Malignant Melanoma.

Randal K Gregg1.   

Abstract

Since the first resection of melanoma by Hunter in 1787, efforts to treat patients with this deadly malignancy have been ongoing. Initial work to understand melanoma biology for therapeutics development began with the employment of isolated cancer cells grown in cell cultures. However, these models lack in vivo interactions with the tumor microenvironment. Melanoma cell line transplantation into suitable animals such as mice has been informative and useful for testing therapeutics as a preclinical model. Injection of freshly isolated patient melanomas into immunodeficient animals has shown the capacity to retain the genetic heterogeneity of the tumors, which is lost during the long-term culture of melanoma cells. Upon advancement of technology, genetically engineered animals have been generated to study the spontaneous development of melanomas in light of newly discovered genetic aberrations associated with melanoma formation. Culturing melanoma cells in a matrix generate tumor spheroids, providing an in vitro environment that promotes the heterogeneity commonplace with human melanoma and displaces the need for animal care facilities. Advanced 3D cultures have been created simulating the structure and cellularity of human skin to permit in vitro testing of therapeutics on melanomas expressing the same phenotype as demonstrated in vivo. This review will discuss these models and their relevance to the study of melanomagenesis, growth, metastasis, and therapy.

Entities:  

Keywords:  B16; BRAF; Genetically engineered mice; Malignant melanoma; NRAS; Tumor spheroids; Ultraviolet light; Xenograft transplantation; YUMM; Zebrafish

Mesh:

Year:  2021        PMID: 33704702     DOI: 10.1007/978-1-0716-1205-7_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  78 in total

1.  Xeroderma pigmentosum genes and melanoma risk.

Authors:  K Paszkowska-Szczur; R J Scott; P Serrano-Fernandez; A Mirecka; P Gapska; B Górski; C Cybulski; R Maleszka; M Sulikowski; L Nagay; J Lubinski; T Dębniak
Journal:  Int J Cancer       Date:  2013-03-13       Impact factor: 7.396

Review 2.  Developments in targeted therapy in melanoma.

Authors:  V C Amann; E Ramelyte; S Thurneysen; R Pitocco; N Bentele-Jaberg; S M Goldinger; R Dummer; J Mangana
Journal:  Eur J Surg Oncol       Date:  2016-11-05       Impact factor: 4.424

Review 3.  Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

Authors:  Alessandro Rossi; Michela Roberto; Martina Panebianco; Andrea Botticelli; Federica Mazzuca; Paolo Marchetti
Journal:  Eur J Pharmacol       Date:  2019-08-22       Impact factor: 4.432

Review 4.  Pathways in melanoma development.

Authors:  Tal H Erlich; David E Fisher
Journal:  G Ital Dermatol Venereol       Date:  2018-02       Impact factor: 2.011

Review 5.  p16.

Authors:  Stefano Serra; Runjan Chetty
Journal:  J Clin Pathol       Date:  2018-08-03       Impact factor: 3.411

Review 6.  Melanoma and genetics.

Authors:  Andrew A Nelson; Hensin Tsao
Journal:  Clin Dermatol       Date:  2009 Jan-Feb       Impact factor: 3.541

7.  RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Nguyen Dinh Thang; Yuji Goto; Kozue Takeda; Osamu Yamanoshita; Machiko Iida; Nobutaka Ohgami; Haruka Tamura; Yoshiyuki Kawamoto; Masashi Kato
Journal:  Dermatol Res Pract       Date:  2011-10-12

8.  Survival rates of patients with metastatic malignant melanoma.

Authors:  A Sandru; S Voinea; E Panaitescu; A Blidaru
Journal:  J Med Life       Date:  2014 Oct-Dec

Review 9.  Cutaneous melanoma: From pathogenesis to therapy (Review).

Authors:  Giulia C Leonardi; Luca Falzone; Rossella Salemi; Antonino Zanghì; Demetrios A Spandidos; James A Mccubrey; Saverio Candido; Massimo Libra
Journal:  Int J Oncol       Date:  2018-02-27       Impact factor: 5.650

Review 10.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.